SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

obudanersen

IONS·IONIS PHARMACEUTICALS INC
NEUTRAL
Drug Impact Rating2/10
Trial phase
unknown (not present in SecBot's Phase 2/3 clinical-trial database; no FDA action or catalyst on record)
Time to market
unknown, no phase, trial, or regulatory filing could be verified from available sources this session; if it is an early-stage antisense program, commercialization would be years away
Why 2/10
No hard, dated catalyst for obudanersen exists in the next ~12 months: the only trace of it this session is its appearance in Ionis's Q2 2026 earnings analysis (listed alongside development code ION775), with no FDA catalyst, clinical-trial record, press release, or readout date found in any SecBot database or web search, it is a small, likely early-stage program inside a ~$9.1B-market-cap company whose near-term binary catalysts are other drugs (zilganersen PDUFA Sept 22, 2026; bepirovirsen PDUFA Oct 26, 2026), so impactScore is 2.
Actionable Insight NEUTRAL

Do not build an Ionis position on obudanersen, it has essentially no public footprint and no dated catalyst, so there is nothing binary to trade. If you hold IONS for other reasons, the near-term share-price drivers are the zilganersen PDUFA on Sept 22, 2026 and the bepirovirsen PDUFA on Oct 26, 2026, and any future Ionis pipeline update that finally reveals obudanersen's indication and phase (its target/indication could not be verified from any source this session).

Price Chart

Loading chart...

Executive Summary

Obudanersen appears to be an early-stage Ionis Pharmaceuticals pipeline program, but there is almost no verifiable public information about it: the only evidence found this session is its mention in the analysis of Ionis's Q2 2026 earnings 8-K (filed July 29, 2026), which names obudanersen together with development code ION775 among ~13 pipeline drugs. Rating is neutral by necessity: there is nothing to evaluate and no dated catalyst. For context, Ionis is a ~$9.1B-market-cap RNA-medicines company whose stock fell 23% on July 9, 2026 after its eplontersen Phase 3 trial (with AstraZeneca) missed its primary endpoint, and whose near-term binary catalysts are other drugs (zilganersen PDUFA Sept 22, 2026; bepirovirsen PDUFA Oct 26, 2026).

How It Works

Almost certainly an antisense oligonucleotide (a synthetic RNA-like molecule that binds to a disease-related gene's messenger RNA to dial down production of a harmful protein), the "-ersen" suffix is the naming convention for this drug class and is used throughout Ionis's pipeline (e.g., eplontersen, olezarsen, zilganersen). However, its specific genetic target and the disease it is meant to treat could NOT be verified from any tool result this session, so treat the mechanism as inferred, not confirmed.

Trial Status

The drug is only verifiable as a named Ionis pipeline program in the local analysis of Ionis's Q2 2026 earnings 8-K, which lists "obudanersen" adjacent to "ION775", the code linkage is inferred from that co-occurrence, not independently confirmed.

The Two-Sided Case

▲ Bull Case3
Obudanersen is a named, active pipeline program at Ionis, it appears in the drug list extracted from the company's Q2 2026 earnings 8-K analysis, alongside development code ION775 (filing analysis, filed 2026-07-29).
Ionis has the resources to carry early programs: the same earnings analysis reports ~$2.1B in cash and short-term investments as of June 30, 2026 and maintained FY2026 revenue guidance of $875-900M.
Company-level analyst sentiment is positive regardless of this program: consensus shows 16 Buy + 11 Strong Buy vs 6 Hold and 0 Sell, with a mean price target of $90.8 vs the $51.77 close.
▼ Bear Case4
Zero verifiable footprint: no FDA action, catalyst, clinical-trial record, press release, or news mention of obudanersen/ION775 was found in any tool result this session, consistent with a very early/preclinical-stage asset that carries high attrition risk and is years from market.
No dated catalyst: with no scheduled readout, PDUFA, or filing for obudanersen, there is no share-price binary to underwrite; it cannot move the stock on its own.
Ionis pipeline execution risk is demonstrably live: the CARDIO-TTRansform Phase 3 miss for eplontersen (with AstraZeneca) cut IONS shares ~23% on July 9, 2026 and drew a Levi & Korsinsky investigation notice, a reminder that Ionis clinical assets fail, and early-stage ones fail most often.
Stock-level caution flags: FINRA short-volume ratios on IONS ran 56-76% through July 2026, and Wolfe Research downgraded IONS from Outperform to Peer Perform on July 16, 2026.

Upcoming Catalysts

  • No obudanersen-specific catalyst identified in any source this session
  • Company-level: zilganersen (Alexander disease) PDUFA date 2026-09-22 under FDA Priority Review
  • Company-level: bepirovirsen (chronic hepatitis B) PDUFA date 2026-10-26 under FDA Priority Review
  • Company-level: salanersen (SMA) granted Breakthrough Therapy Designation per 2026-07-29 filing analysis; watch for phase/readout details
  • Watch Ionis corporate pipeline updates for first disclosure of obudanersen's indication and phase

Source Filing

The SecBot filing or press-release report that triggered this drug report:

IONIS PHARMACEUTICALS INC 8-K IONS ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 prnewswire.com3 prnewswire.com